Table 3.
EORTC QLQ-C30 questionnaires of the entire study cohort at first diagnosis (T0) and 12 months thereafter (T1)
| EORTC QLQ-C30 | Key | T0 | T1 | T0–> T1 | ||||
|---|---|---|---|---|---|---|---|---|
| n = 112 | Mean | SD | Mean | SD | Changes | IQR | p-values | |
| Global health status/QoL | QL | 47.92 | 21.40 | 54.28 | 24.43 | 6.46 | − 8.3 to 16.7 | 0.006* |
| Physical functioning | PF | 62.70 | 24.79 | 58.15 | 24.95 | − 4.56 | − 20.0 to 13.3 | 0.063 |
| Role functioning | RF | 54.35 | 34.57 | 52.23 | 34.47 | − 2.25 | − 16.7 to 16.7 | 0.531 |
| Emotional functioning | EF | 50.61 | 22.55 | 58.04 | 28.30 | 7.58 | − 8.3 to 25.0 | 0.006* |
| Cognitive functioning | CF | 59.70 | 27.00 | 57.59 | 28.25 | − 1.82 | − 16.7 to 16.7 | 0.495 |
| Social functioning | SF | 60.49 | 30.81 | 57.89 | 32.27 | − 3.40 | − 16.7 to 16.7 | 0.269 |
| Fatigue | FA | 52.83 | 27.39 | 53.87 | 26.15 | 0.91 | − 11.1 to 11.1 | 0.737 |
| Nausea and vomiting | NV | 10.06 | 19.41 | 10.42 | 20.79 | 0.45 | 0–0 | 0.845 |
| Pain | PA | 37.74 | 35.56 | 38.39 | 33.98 | 0.63 | − 16.7 to 33.3 | 0.860 |
| Dyspnea | DY | 52.73 | 37.97 | 54.65 | 36.57 | 1.53 | − 33.3 to 33.3 | 0.680 |
| Insomnia | SL | 47.04 | 36.73 | 42.26 | 37.79 | − 5.61 | − 33.3 to 33.3 | 0.171 |
| Appetite loss | AP | 38.84 | 35.12 | 30.36 | 37.68 | − 9.17 | − 33.3 to 0 | 0.015* |
| Constipation | CO | 26.67 | 37.01 | 21.32 | 32.51 | − 5.20 | − 33.3 to 0 | 0.159 |
| Diarrhea | DI | 13.03 | 26.63 | 15.32 | 25.23 | 2.45 | 0–0 | 0.426 |
| Financial difficulties | FI | 20.32 | 29.28 | 27.38 | 30.61 | 6.98 | 0–33.3 | 0.01* |
EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer quality-of-life questionnaire; IQR Interquartile range; n number of patients; SD standard deviation. p-values (two-sided, paired t-test) for longitudinal changes between T0 and T1
Significant p-values are indicated: *p-value < 0.05